Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

JOURNAL OF CLINICAL ONCOLOGY

LIPPINCOTT WILLIAMS & WILKINS

1. Pfizer Inc